CareDx, Inc. (CDNA) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $6.4M sold). Latest close $74.44 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.
Deerfield Management · First Eagle Investment Management — 2 tracked funds hold CDNA. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 16 sales ($6.4M). Insider trading
Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deerfield Management | 0.59% | 1,997,618 | TRIMMED (-8.8%) Q3 filed Nov 16 |
| First Eagle Investment Management | 0.03% | 598,497 | ADDED (+4.0%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +154.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 226 of 8,857 filers |
| Long-only filers among them | 226 |
| Change vs 2026 Q1 | +42 net · 221 entered · 179 exited |
| Shares reported, all filers | 52,784,868 |
| Reported value, all filers | $1.5B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories (SIC 8071) |
| Revenue · FY2025 | $379.8M |
| Net income · FY2025 | $-21.4M |
| Total assets · FY2025 | $413.2M |
| Shares outstanding | 52,542,786 |
| Market cap (at latest close) | $3.9B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.
| Shares short · Oct 15, 2026 | 6,715,367 |
| Share of shares outstanding | 12.78% |
| Days to cover | 4.49 |
Shares short at recent settlements — Jul 31, 2026: 6.1M · Aug 14, 2026: 5.8M · Aug 31, 2026: 5.8M · Sep 15, 2026: 6.3M · Sep 30, 2026: 6.6M · Oct 15, 2026: 6.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 348 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 27 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 26, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 16 sales by 3 insiders ($6.4M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Kennedy Keith | CFO & COO | Sell | 800 | $78.78 | $63.0K | SEC filing |
| Nov 12, 2026 | Kennedy Keith | CFO & COO | Sell | 1,297 | $79.61 | $103.3K | SEC filing |
| Nov 12, 2026 | Goldberg Michael | Sell | 3,547 | $78.32 | $277.8K | SEC filing | |
| Nov 12, 2026 | Goldberg Michael | Sell | 8,024 | $79.32 | $636.5K | SEC filing | |
| Nov 12, 2026 | Goldberg Michael | Sell | 2,229 | $79.85 | $178.0K | SEC filing | |
| Nov 10, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | Sell | 2,996 | $80.47 | $241.1K | SEC filing |
| Nov 10, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | Sell | 200 | $81.05 | $16.2K | SEC filing |
| Nov 10, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | Sell | 900 | $83.33 | $75.0K | SEC filing |
| Nov 5, 2026 | Kennedy Keith | CFO & COO | Sell | 28,256 | $76.55 | $2.2M | SEC filing |
| Nov 5, 2026 | Kennedy Keith | CFO & COO | Sell | 12,380 | $77.42 | $958.4K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | PETER MAAG | Director | 9,122 | $423.1K | Aug 17, 2026 | SEC filing |
| Aug 14, 2026 | PETER MAAG | Director | 7,000 | $317.1K | Aug 14, 2026 | SEC filing |
| Aug 13, 2026 | PETER MAAG | Director | 7,000 | $329.5K | Aug 13, 2026 | SEC filing |
| Aug 12, 2026 | PETER MAAG | Director | 7,000 | $328.2K | Aug 12, 2026 | SEC filing |
| Aug 11, 2026 | PETER MAAG | Director | 7,000 | $333.9K | Aug 11, 2026 | SEC filing |
| Aug 10, 2026 | PETER MAAG | Director | 6,902 | $328.9K | Aug 10, 2026 | SEC filing |
| Aug 10, 2026 | ARTHUR TORRES | Director | 4,200 | $200.5K | Aug 10, 2026 | SEC filing |
| Aug 7, 2026 | PETER MAAG | Director | 27,332 | $1.3M | Aug 7, 2026 | SEC filing |
| Aug 5, 2026 | PETER MAAG | Director | 46,963 | $2.2M | Aug 5, 2026 | SEC filing |
| Aug 5, 2026 | JEFFREY NOVACK | Officer | 2,688 | $126.6K | Aug 5, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | BAMCO INC /NY/ | SC 13G/A | 1,662,887 | 3.2% | Jun 30, 2026 | SEC filing |
| Aug 7, 2026 | Gagnon Securities LLC | SC 13G/A | 1,629,867 | 3.2% | Jul 31, 2026 | SEC filing |
| Aug 7, 2026 | STATE STREET CORPORATION | SC 13G | 2,468,858 | 4.8% | Jun 30, 2026 | SEC filing |
| Jul 27, 2026 | BlackRock, Inc. | SC 13G/A | 4,664,092 | 9.0% | Jun 30, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 12, 2026 | Gagnon Securities LLC | SC 13G/A | 2,213,827 | 4.3% | Dec 31, 2025 | SEC filing |
| Feb 9, 2026 | STATE STREET CORPORATION | SC 13G | 2,737,752 | 5.3% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | BAMCO INC /NY/ | SC 13G | 2,721,072 | 5.1% | Sep 30, 2025 | SEC filing |
| Oct 30, 2025 | The Vanguard Group | SC 13G/A | 3,749,707 | 7.0% | Sep 30, 2025 | SEC filing |
| Jul 24, 2025 | Gagnon Securities LLC | SC 13G | 2,134,124 | 3.8% | Jul 17, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Services-Medical Laboratories (SIC 8071). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 123 Lobbying Disclosure Act filings named this company as client, 2015–2026; most common issues: Health Issues (89), Medicare/Medicaid (30), Medical/Disease Research/Clinical Labs (13).
Federal contracts: $19.0M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $682.2K |
| FY2022 | $2.0M |
| FY2023 | $3.1M |
| FY2024 | $1.4M |
| FY2025 | $4.9M |
| FY2026 | $6.9M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C25226N0586 | Department of Veterans Affairs | $2.5M | Sep 29, 2026 |
| 36C25225N0010 | Department of Veterans Affairs | $2.4M | Oct 1, 2024 |
| 36C25223N0621 | Department of Veterans Affairs | $2.0M | Sep 30, 2023 |
| 36C25226N0079 | Department of Veterans Affairs | $1.6M | Feb 1, 2026 |
| 36C25626N0370 | Department of Veterans Affairs | $1.6M | Apr 1, 2026 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Gross Profitability (Novy-Marx) — Gross profit / assets: 53.8% · Gross margin: 64.2%
· Distress Risk (Altman Z″) — Z″-Score: -0.76 · Working capital / assets: 0.40 · Retained earnings / assets: -1.78 · EBIT / assets: -0.07 · Equity / liabilities: 2.75
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold CDNA — ranked by lift, the co-holding pattern described in Methodology: Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) · EXAGEN INC. (XGN) · BillionToOne, Inc. (BLLN) · HCA Healthcare, Inc. (HCA).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 16, 2026 · 8-K/A | 2.01 Completion of Acquisition or Disposition of Assets · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 30, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Natera, Inc. (NTRA) · Track Record: how the signals scored · Practice timing on CDNA
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.